Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
RXi Pharmaceuticals Corporation was a clinical-stage RNAi company that specialized in developing the next generation of RNAi-based therapeutics for a variety of indications, including dermatology and ophthalmology. The company utilized its proprietary self-delivering RNAi (sd-rxRNA®) platform technology to create therapies designed to silence disease-causing genes. RXi Pharmaceuticals focused on areas with significant unmet medical needs. In November 2018, RXi Pharmaceuticals Corp. was renamed Phio Pharmaceuticals Corp. (NASDAQ: PHIO) and shifted its primary focus to immuno-oncology applications of RNAi technology.
The headquarters housed the company's core operations, including its research and development labs focused on RNAi therapeutics, clinical program management, and corporate administrative functions.
As a biotech R&D facility, it would have included specialized laboratory spaces equipped for molecular biology, cell culture, and formulation development essential for its RNAi platform technology. Specific architectural details are not publicly highlighted.
The work culture at RXi Pharmaceuticals, typical of a clinical-stage biotech, likely fostered innovation, scientific excellence, and a collaborative, fast-paced environment. Employees were driven by the potential of RNAi technology to address unmet medical needs and improve patient outcomes.
Located in Marlborough, MA, the headquarters benefited from the rich biotech ecosystem of the Greater Boston area, offering access to talent, research institutions, and industry partners, crucial for its R&D activities and collaborations.
As a clinical-stage biotechnology company, RXi Pharmaceuticals Corp.'s primary focus was on research and development, largely conducted from its US headquarters in Massachusetts. While its therapeutic ambitions had global implications, its operational global presence in terms of international offices was limited during its time as RXi Pharmaceuticals. Collaborations or clinical trials might have involved international partners or sites, but it did not maintain a significant network of global offices under the RXi name.
257 Simarano Drive, Suite 101
Marlborough
Massachusetts
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, RXi Pharmaceuticals Corp' leadership includes:
RXi Pharmaceuticals Corp has been backed by several prominent investors over the years, including:
In its final year of operation as RXi Pharmaceuticals, key executive developments included the appointment of a new COO to strengthen operations. The most significant event was the company's strategic rebranding to Phio Pharmaceuticals in November 2018, with much of the existing leadership transitioning to the new entity.
Discover the tools RXi Pharmaceuticals Corp uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While RXi Pharmaceuticals Corp. is now Phio Pharmaceuticals and its original email domain (@rxipharma.com) is no longer in active use, common email patterns for companies like RXi often included combinations of first initial and last name, or first name and last name separated by a dot.
[first_initial][last]@rxipharma.com (e.g., jdoe@rxipharma.com), or [first].[last]@rxipharma.com (e.g., jane.doe@rxipharma.com)
Format
gdispersyn@rxipharma.com (Example using a known past executive and common format; domain is no longer active)
Example
0%
Success rate
GlobeNewswire • January 8, 2018
RXi Pharmaceuticals Corporation (NASDAQ: RXII) today announced that it has appointed Gerrit Dispersyn, Dr.med.vet., Ph.D., MBA, an accomplished pharmaceutical executive with extensive experience in drug development and corporate strategy, as its Chief Operating Officer, effective immediately. In this new role, Dr. Dispersyn will be responsible for managing the Company's operations, including clinical development, manufacturing and program management....more
GlobeNewswire • November 12, 2018
RXi Pharmaceuticals Corporation (NASDAQ: RXII) today announced that it has changed its name to Phio Pharmaceuticals Corp. This name change reflects the Company's primary focus on immuno-oncology. In connection with the name change, the Company's ticker symbol on The Nasdaq Capital Market will change from 'RXII' to 'PHIO', effective at the open of trading on November 13, 2018....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including RXi Pharmaceuticals Corp, are just a search away.